Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan

References

• Aboutaleb, N., Jamali, H., Abolhasani, M., & Pazoki Toroudi, H. (2019). Lavender oil (Lavandula angustifolia) attenuates renal ischemia/reperfusion injury in rats through suppression of inflammation, oxidative stress and apoptosis. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 110, 9–19. https://doi.org/10.1016/j.biopha.2018.11.045
   PubMed Web of Science ®Google Scholar
• Baldinger, P., Höflich, A. S., Mitterhauser, M., Hahn, A., Rami-Mark, C., Spies, M., Wadsak, W., Lanzenberger, R., & Kasper, S. (2015). Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: A randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. International Journal of Neuropsychophar­macology., 18(4), pyu063–pyu063. https://doi.org/10.1093/ijnp/pyu063
   Web of Science ®Google Scholar
• Bartova, L., Dold, M., Volz, H. P., Seifritz, E., Möller, H. J., & Kasper, S. (2022a). Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. European Archives of Psychiatry and Clinical Neuroscience, 273(1), 51–63. https://doi.org/10.1007/s00406-022-01390-z
   PubMedGoogle Scholar
• Caspersen, I. H., Magnus, P., & Trogstad, L. (2022). Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. European Journal of Epidemiology, 37(5), 539–548. https://doi.org/10.1007/s10654-022-00847-8
   PubMed Web of Science ®Google Scholar
• Crook, H., Raza, S., Nowell, J., Young, M., & Edison, P. (2021). Long covid-mechanisms, risk factors, and management. British Medical Journal (Clinical Research Ed.), 374, n1648. https://doi.org/10.1136/bmj.n1648
   PubMedGoogle Scholar
• Damiano, R. F., Caruso, M. J. G., Cincoto, A. V., de Almeida Rocca, C. C., de Pádua Serafim, A., Bacchi, P., Guedes, B. F., Brunoni, A. R., Pan, P. M., Nitrini, R., Beach, S., Fricchione, G., Busatto, G., Miguel, E. C., & Forlenza, O. V, (2022). Post-COVID-19 psychiatric and cognitive morbidity: Preliminary findings from a Brazilian cohort study. General Hospital Psychiatry, 75, 38–45. https://doi.org/10.1016/j.genhosppsych.2022.01.002
   PubMed Web of Science ®Google Scholar
• Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re’em, Y., Redfield, S., Austin, J. P., & Akrami, A. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 38, 101019. https://doi.org/10.1016/j.eclinm.2021.101019
   PubMedGoogle Scholar
• Doroshyenko, O., Rokitta, D., Zadoyan, G., Klement, S., Schläfke, S., Dienel, A., Gramatté, T., Lück, H., & Fuhr, U. (2013). Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 41(5), 987–993. https://doi.org/10.1124/dmd.112.050203
   PubMed Web of Science ®Google Scholar
• Doykov, I., Hällqvist, J., Gilmour, K. C., Grandjean, L., Mills, K., & Heywood, W. E. (2020). The long tail of Covid-19’ – The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Research, 9, 1349. https://doi.org/10.12688/f1000research.27287.2
   PubMedGoogle Scholar
• EMA/HMPC/143181/2010. (2012). Community herbal monograph on Lavandula angustifolia Miller, aetheroleum (europa.eu), 27 March.
   Google Scholar
• Friedland, K., Silani, G., Schuwald, A., Stockburger, C., Koch, E., Nöldner, M., & Müller, W. E. (2021). Neurotrophic properties of Silexan, an essential oil from the flowers of lavender-preclinical evidence for antidepressant-like properties. Pharmacopsychiatry, 54(1), 37–46. https://doi.org/10.1055/a-1293-8585
   PubMedGoogle Scholar
• Gastpar, M., Müller, W. E., Volz, H. P., Möller, H. J., Schläfke, S., Dienel, A., & Kasper, S. (2017). Silexan does not cause withdrawal symptoms even when abruptly discontinued. International Journal of Psychiatry in Clinical Practice, 21(3), 177–180. https://doi.org/10.1080/13651501.2017.1301488
   PubMed Web of Science ®Google Scholar
• Kappelmann, N., Dantzer, R., & Khandaker, G. M. (2021). Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology, 131, 105295. https://doi.org/10.1016/j.psyneuen.2021.105295
   PubMed Web of Science ®Google Scholar
• Kasper, S., Möller, H. J., Volz, H. P., Schläfke, S., & Dienel, A. (2017). Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. International Clinical Psychopharmacology, 32(4), 195–204. https://doi.org/10.1097/YIC.0000000000000176
   PubMed Web of Science ®Google Scholar
• Kasper, S., Müller, W. E., Volz, H. P., Möller, H. J., Koch, E., & Dienel, A. (2018). Silexan in anxiety disorders: Clinical data and pharmacological background. The World Journal of Biological Psychiatry : The Official Journal of the World Federation of Societies of Biological Psychiatry, 19(6), 412–420. https://doi.org/10.1080/15622975.2017.1331046
   PubMed Web of Science ®Google Scholar
• Kasper, S., Volz, H. P., Dienel, A., & Schläfke, S. (2016). Efficacy of Silexan in mixed anxiety-depression–A randomized, placebo-controlled trial. European Neuropsychopharmacology : The Journal of the European College of Neuropsychopharmacology, 26(2), 331–340. https://doi.org/10.1016/j.euroneuro.2015.12.002
   PubMed Web of Science ®Google Scholar
• López, V., Nielsen, B., Solas, M., Ramírez, M. J., & Jäger, A. K. (2017). Exploring pharmacological mechanisms of lavender (Lavandula angustifolia) essential oil on central nervous system targets. Frontiers in Pharmacology, 8, 280. https://doi.org/10.3389/fphar.2017.00280
   PubMed Web of Science ®Google Scholar
• Möller, H. J., Volz, H. P., Dienel, A., Schläfke, S., & Kasper, S. (2019). Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 269(2), 183–193. https://doi.org/10.1007/s00406-017-0852-4
   PubMed Web of Science ®Google Scholar
• Möller, H. J., Volz, H. P., Seifritz, E., Müller, H., Kenntner-Mabiala, R., Kaussner, Y., Schoch, S., & Kasper, S. (2021). Silexan does not affect driving performance after single and multiple dose applications: results from a double-blind, placebo and reference-controlled study in healthy volunteers. Journal of Psychiatric Research, 136, 543–551. https://doi.org/10.1016/j.jpsychires.2020.10.028
   PubMed Web of Science ®Google Scholar
• Mueller, J. K., Riederer, P., & Müller, W. E. (2022). Neuropsychiatric drugs against COVID-19: What is the clinical evidence? Pharmacopsychiatry, 55(1), 7–15. https://doi.org/10.1055/a-1717-2381
   PubMedGoogle Scholar
• Pandur, E., Balatinácz, A., Micalizzi, G., Mondello, L., Horváth, A., Sipos, K., & Horváth, G. (2021). Anti-inflammatory effect of lavender (Lavandula angustifolia Mill.) essential oil prepared during different plant phenophases on THP-1 macrophages. BMC Complementary Medicine and Therapies, 21(1), 287. https://doi.org/10.1186/s12906-021-03461-5
   PubMedGoogle Scholar
• Peter, R. S., Nieters, A., Kräusslich, H. G., Brockmann, S. O., Göpel, S., Kindle, G., Merle, U., Steinacker, J. M., Rothenbacher, D., Kern, W. V., EPILOC Phase 1 Study Group. (2022). Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379:e071050. doi:.10.1136/bmj-2022-071050
   Google Scholar
• Phetsouphanh, C., Darley, D. R., Wilson, D. B., Howe, A., Munier, C. M. L., Patel, S. K., Juno, J. A., Burrell, L. M., Kent, S. J., Dore, G. J., Kelleher, A. D., & Matthews, G. V. (2022). Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology, 23(2), 210–216. https://doi.org/10.1038/s41590-021-01113-x
   PubMed Web of Science ®Google Scholar
• . Premraj, L., Kannapadi, N. V., Briggs, J., Seal, S. M., Battaglini, D., Fanning, J., Suen, J., Robba, C., Fraser, J., & Cho, S. M. (2022). Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. Journal of the Neurological Sciences, 434, 120162. https://doi.org/10.1016/j.jns.2022.120162
   PubMed Web of Science ®Google Scholar
• Sánchez-Vidaña, D. I., Po, K. K., Fung, T. K., Chow, J. K., Lau, W. K., So, P. K., Lau, B. W., & Tsang, H. W. (2019). Lavender essential oil ameliorates depression-like behavior and increases neurogenesis and dendritic complexity in rats. Neuroscience Letters, 701, 180–192. https://doi.org/10.1016/j.neulet.2019.02.042
   PubMed Web of Science ®Google Scholar
• Schuwald, A., Nöldner, M., Wilmes, T., Klugbauer, N., Leuner, K., & Müller, W. E. (2013). Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLOS One., 8(4), e59998. https://doi.org/10.1371/journal.pone.0059998
   PubMed Web of Science ®Google Scholar
• Seifritz, E., Möller, H. J., Volz, H. P., Müller, W. E., Hopyan, T., Wacker, A., Schläfke, S., & Kasper, S. (2021). No abuse potential of Silexan in healthy recreational drug users: A randomized controlled trial. The International Journal of Neuropsychopharmacology, 24(3), 171–180. https://doi.org/10.1093/ijnp/pyaa064
   PubMed Web of Science ®Google Scholar
• Seifritz, E., Kasper, S., Möller, H. J., Volz, H. P., Müller, W. E., Eckert, A., & Hatzinger, M. (2022). Effect of anxiolytic drug silexan on sleep - a narrative review. The World Journal of Biological Psychiatry : The Official Journal of the World Federation of Societies of Biological Psychiatry, 23(7), 493–500. https://doi.org/10.1080/15622975.2021.2013092
   PubMed Web of Science ®Google Scholar
• Seifritz, E., Schläfke, S., & Holsboer-Trachsler, E. (2019). Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect. Journal of Psychiatric Research, 115, 69–74. https://doi.org/10.1016/j.jpsychires.2019.04.013
   PubMed Web of Science ®Google Scholar
• Silva, G. L., Luft, C., Lunardelli, A., Amaral, R. H., Melo, D. A., Donadio, M. V., Nunes, F. B., de Azambuja, M. S., Santana, J. C., Moraes, C. M., Mello, R. O., Cassel, E., Pereira, M. A., & de Oliveira, J. R. (2015). Antioxidant, analgesic and anti-inflammatory effects of lavender essential oil. Anais Da Academia Brasileira De Ciências, 87(2 Suppl), 1397–1408. https://doi.org/10.1590/0001-3765201520150056
   PubMed Web of Science ®Google Scholar
• Stein, M. B. COVID-19: psychiatric illness. UpToDate. Literature review current through: Jul 2022. | This topic last updated: Aug 10, 2022. Available online: https://www.uptodate.com/contents/covid-19-psychiatric-illness/print
   Google Scholar
• Uzunova, G., Pallanti, S., & Hollander, E. (2021). Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase. International Journal of Psychiatry in Clinical Practice, 25(2), 115–131. https://doi.org/10.1080/13651501.2021.1887264
   PubMed Web of Science ®Google Scholar
• Volz, H. P. (2022a). Lavendel bei Angststörungen – Schwerpunkt Lavendelöl. Zeitschrift Für Phytotherapie, 43(03), 105–111. https://doi.org/10.1055/a-1883-6090
   Google Scholar
• Volz, H. P., & Klement, S. (2022b). Influence of Silexan on functional impairment in patients with anxiety disorders – an analysis of pooled data. Zeitschrift Für Phytotherapie, 43(S 01), S49. https://doi.org/10.1055/s-0042-1749295
   Google Scholar
• Bartova, L., Dold, M., Fugger, G., Weidenauer, A., Rujescu, D., & Kasper, S. (2022b). Silexan for treatment of anxiety and depression in the context of COVID-19. Eur Neuropsychopharmacol. 2023;70:47–48. doi: 10.1016/j.euroneuro.2023.02.015.
   Google Scholar
• Volz, H. P., Saliger, J., Kasper, S., Möller, H. J., & Seifritz, E. (2021). Subsyndromal operational anxiety disorder: operationalization and epidemiology – a systematic literature survey. Int J Psychiatry Clin Pract, 27, 1–10. https://doi.org/10.1080/13651501.2021.1941120
   Google Scholar
• Volz, H. P., Stirnweiß, J., Kasper, S., Möller, H. J., & Seifritz, E. (2022). Subthreshold depression – concept, operationalisation and epidemiological data. A Scoping Review. International Journal of Psychiatry in Clinical Practice, 23, 1–15. https://doi.org/10.1080/13651501.2022.2087530
   Google Scholar
• von Känel, R., Kasper, S., Bondolfi, G., Holsboer-Trachsler, E., Hättenschwiler, J., Hatzinger, M., Imboden, C., Heitlinger, E., & Seifritz, E. (2021). Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis. Brain and Behavior, 11(4), e01997. https://doi.org/10.1002/brb3.1997
   PubMed Web of Science ®Google Scholar
• Westerlind, E., Palstam, A., Sunnerhagen, K. S., & Persson, H. C. (2021). Patterns and predictors of sick leave after Covid-19 and long Covid in a national Swedish cohort. BMC Public Health, 21(1), 1023. https://doi.org/10.1186/s12889-021-11013-2
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. N/N05/N05B/N05BX. Last updated: 2021-12-14. Available online at: https://www.whocc.no/atc_ddd_index/?code=N05BX&showdescription=no
   Google Scholar
• Xie, Y., Xu, E., & Al-Aly, Z. (2022). Risks of mental health outcomes in people with COVID-19: cohort study. British Medical Journal, 376, e068993. https://doi.org/10.1136/bmj-2021-068993
   PubMedGoogle Scholar
• Zürcher, S. J., Banzer, C., Adamus, C., Lehmann, A. I., Richter, D., & Kerksieck, P. (2022). Post-viral mental health sequelae in infected persons associated with COVID-19 and previous epidemics and pandemics: Systematic review and meta-analysis of prevalence estimates. Journal of Infection and Public Health, 15(5), 599–608. https://doi.org/10.1016/j.jiph.2022.04.005
   PubMed Web of Science ®Google Scholar